The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
Zacks.com on MSN6d
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast CancerThe FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...
The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human ...
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback